Profound Medical Corp PROF

Primary Symbol: T.PRN

Healthcare Medical Devices

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

TSX:PRN - Post by User

Profound Medical Corp > Q3 2021 Financial Results Nov 4 - Conference call to follow

<< Previous

Bullboard Posts

Next >>

Post by HomerAndCompanyon Nov 03, 2021 11:30am

157 Views

Post# 34082321

Q3 2021 Financial Results Nov 4 - Conference call to follow

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

 Third Quarter 2021 Results Conference Call Details: Date: Thursday, November 4, 2021 Time: 4:30 p.m. ET Live Call: 1-800-773-2954 (Canada and the United States) 1-847-413-3731 (International) Conference ID: 50245581

The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?